AI assistant
Sending…
Phathom Pharmaceuticals, Inc. — Director's Dealing 2021
Jan 29, 2021
32407_dirs_2021-01-29_0da6581e-f049-4e51-8855-5a1cd354d5a3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2021-01-28
Reporting Person: Curran Terrie (Director, President and Chief Executive)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-28 | Stock Option (Right to Buy) | $39.11 | A | 225000 | Acquired | 2031-01-27 | Common Stock (225000) | Direct |
Footnotes
F1: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
More from Phathom Pharmaceuticals, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Regulatory Filings
2026
Mar 27
Director's Dealing
2026
Mar 3
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12